nodes	percent_of_prediction	percent_of_DWPC	metapath
Linagliptin—Dipeptidyl Peptidase 4 Inhibitors—Sitagliptin—type 2 diabetes mellitus	0.519	1	CiPCiCtD
Linagliptin—DPP4—type 2 diabetes mellitus	0.172	0.853	CbGaD
Linagliptin—DPP4—Sitagliptin—type 2 diabetes mellitus	0.146	0.716	CbGbCtD
Linagliptin—CYP3A4—type 2 diabetes mellitus	0.0297	0.147	CbGaD
Linagliptin—ABCB1—Sitagliptin—type 2 diabetes mellitus	0.0087	0.0426	CbGbCtD
Linagliptin—ABCB1—Chlorpropamide—type 2 diabetes mellitus	0.00629	0.0308	CbGbCtD
Linagliptin—CYP3A4—Sitagliptin—type 2 diabetes mellitus	0.00521	0.0255	CbGbCtD
Linagliptin—CYP3A4—Glipizide—type 2 diabetes mellitus	0.00477	0.0234	CbGbCtD
Linagliptin—ABCB1—Bromocriptine—type 2 diabetes mellitus	0.00432	0.0212	CbGbCtD
Linagliptin—CYP3A4—Repaglinide—type 2 diabetes mellitus	0.00416	0.0204	CbGbCtD
Linagliptin—CYP3A4—Pioglitazone—type 2 diabetes mellitus	0.00377	0.0185	CbGbCtD
Linagliptin—ABCB1—Glyburide—type 2 diabetes mellitus	0.00322	0.0158	CbGbCtD
Linagliptin—ABCB1—Losartan—type 2 diabetes mellitus	0.00294	0.0144	CbGbCtD
Linagliptin—CYP3A4—Nateglinide—type 2 diabetes mellitus	0.00285	0.014	CbGbCtD
Linagliptin—CYP3A4—Orlistat—type 2 diabetes mellitus	0.00274	0.0134	CbGbCtD
Linagliptin—CYP3A4—Irbesartan—type 2 diabetes mellitus	0.00274	0.0134	CbGbCtD
Linagliptin—CYP3A4—Bromocriptine—type 2 diabetes mellitus	0.00259	0.0127	CbGbCtD
Linagliptin—CYP3A4—Glyburide—type 2 diabetes mellitus	0.00193	0.00945	CbGbCtD
Linagliptin—CYP3A4—Losartan—type 2 diabetes mellitus	0.00176	0.00864	CbGbCtD
Linagliptin—Alogliptin—DPP4—type 2 diabetes mellitus	0.00158	0.853	CrCbGaD
Linagliptin—Alogliptin—CYP3A4—type 2 diabetes mellitus	0.000273	0.147	CrCbGaD
Linagliptin—DPP4—islet of Langerhans—type 2 diabetes mellitus	0.000159	0.131	CbGeAlD
Linagliptin—DPP4—nephron tubule—type 2 diabetes mellitus	0.000128	0.106	CbGeAlD
Linagliptin—Myalgia—Glipizide—type 2 diabetes mellitus	0.000125	0.00252	CcSEcCtD
Linagliptin—Arthralgia—Glipizide—type 2 diabetes mellitus	0.000125	0.00252	CcSEcCtD
Linagliptin—Angioedema—Sitagliptin—type 2 diabetes mellitus	0.000125	0.00252	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Rosiglitazone—type 2 diabetes mellitus	0.000125	0.00251	CcSEcCtD
Linagliptin—Headache—Tolbutamide—type 2 diabetes mellitus	0.000124	0.00251	CcSEcCtD
Linagliptin—Upper respiratory tract infection—Valsartan—type 2 diabetes mellitus	0.000124	0.00251	CcSEcCtD
Linagliptin—Constipation—Repaglinide—type 2 diabetes mellitus	0.000124	0.0025	CcSEcCtD
Linagliptin—Diarrhoea—Chlorpropamide—type 2 diabetes mellitus	0.000124	0.00249	CcSEcCtD
Linagliptin—Hypersensitivity—Nateglinide—type 2 diabetes mellitus	0.000123	0.00249	CcSEcCtD
Linagliptin—Upper respiratory tract infection—Orlistat—type 2 diabetes mellitus	0.000123	0.00248	CcSEcCtD
Linagliptin—Arthralgia—Pioglitazone—type 2 diabetes mellitus	0.00012	0.00241	CcSEcCtD
Linagliptin—Myalgia—Pioglitazone—type 2 diabetes mellitus	0.00012	0.00241	CcSEcCtD
Linagliptin—Pancreatitis—Metformin—type 2 diabetes mellitus	0.00012	0.00241	CcSEcCtD
Linagliptin—Infestation—Valsartan—type 2 diabetes mellitus	0.000119	0.0024	CcSEcCtD
Linagliptin—Infestation NOS—Valsartan—type 2 diabetes mellitus	0.000119	0.0024	CcSEcCtD
Linagliptin—Cough—Sitagliptin—type 2 diabetes mellitus	0.000119	0.0024	CcSEcCtD
Linagliptin—Nasopharyngitis—Irbesartan—type 2 diabetes mellitus	0.000119	0.0024	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Pioglitazone—type 2 diabetes mellitus	0.000119	0.0024	CcSEcCtD
Linagliptin—Diarrhoea—Acarbose—type 2 diabetes mellitus	0.000119	0.00239	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Rosiglitazone—type 2 diabetes mellitus	0.000118	0.00238	CcSEcCtD
Linagliptin—Infestation—Orlistat—type 2 diabetes mellitus	0.000118	0.00238	CcSEcCtD
Linagliptin—Infestation NOS—Orlistat—type 2 diabetes mellitus	0.000118	0.00238	CcSEcCtD
Linagliptin—Constipation—Rosiglitazone—type 2 diabetes mellitus	0.000117	0.00236	CcSEcCtD
Linagliptin—Myalgia—Sitagliptin—type 2 diabetes mellitus	0.000116	0.00234	CcSEcCtD
Linagliptin—Arthralgia—Sitagliptin—type 2 diabetes mellitus	0.000116	0.00234	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Sitagliptin—type 2 diabetes mellitus	0.000116	0.00233	CcSEcCtD
Linagliptin—Urticaria—Repaglinide—type 2 diabetes mellitus	0.000115	0.00232	CcSEcCtD
Linagliptin—DPP4—cardiovascular system—type 2 diabetes mellitus	0.000115	0.0951	CbGeAlD
Linagliptin—Anaphylactic shock—Pioglitazone—type 2 diabetes mellitus	0.000115	0.00231	CcSEcCtD
Linagliptin—Urinary tract infection—Orlistat—type 2 diabetes mellitus	0.000115	0.00231	CcSEcCtD
Linagliptin—Diarrhoea—Nateglinide—type 2 diabetes mellitus	0.000115	0.00231	CcSEcCtD
Linagliptin—Infection—Pioglitazone—type 2 diabetes mellitus	0.000114	0.0023	CcSEcCtD
Linagliptin—Rash—Tolazamide—type 2 diabetes mellitus	0.000114	0.0023	CcSEcCtD
Linagliptin—Rash—Chlorpropamide—type 2 diabetes mellitus	0.000114	0.0023	CcSEcCtD
Linagliptin—Upper respiratory tract infection—Metformin—type 2 diabetes mellitus	0.000113	0.00228	CcSEcCtD
Linagliptin—Headache—Chlorpropamide—type 2 diabetes mellitus	0.000113	0.00228	CcSEcCtD
Linagliptin—Headache—Tolazamide—type 2 diabetes mellitus	0.000113	0.00228	CcSEcCtD
Linagliptin—Malnutrition—Glyburide—type 2 diabetes mellitus	0.000113	0.00228	CcSEcCtD
Linagliptin—Pancreatitis—Irbesartan—type 2 diabetes mellitus	0.000113	0.00227	CcSEcCtD
Linagliptin—DPP4—kidney—type 2 diabetes mellitus	0.000112	0.093	CbGeAlD
Linagliptin—Anaphylactic shock—Glimepiride—type 2 diabetes mellitus	0.000112	0.00225	CcSEcCtD
Linagliptin—DPP4—pancreas—type 2 diabetes mellitus	0.000112	0.0924	CbGeAlD
Linagliptin—Skin disorder—Pioglitazone—type 2 diabetes mellitus	0.000112	0.00225	CcSEcCtD
Linagliptin—Anaphylactic shock—Sitagliptin—type 2 diabetes mellitus	0.000112	0.00225	CcSEcCtD
Linagliptin—Infection—Sitagliptin—type 2 diabetes mellitus	0.000111	0.00223	CcSEcCtD
Linagliptin—Hypoglycaemia—Ramipril—type 2 diabetes mellitus	0.00011	0.00222	CcSEcCtD
Linagliptin—DPP4—cortex of kidney—type 2 diabetes mellitus	0.00011	0.0906	CbGeAlD
Linagliptin—Rash—Acarbose—type 2 diabetes mellitus	0.000109	0.00221	CcSEcCtD
Linagliptin—Dermatitis—Acarbose—type 2 diabetes mellitus	0.000109	0.0022	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Glipizide—type 2 diabetes mellitus	0.000109	0.0022	CcSEcCtD
Linagliptin—Urticaria—Rosiglitazone—type 2 diabetes mellitus	0.000109	0.00219	CcSEcCtD
Linagliptin—Infestation—Metformin—type 2 diabetes mellitus	0.000109	0.00219	CcSEcCtD
Linagliptin—Infestation NOS—Metformin—type 2 diabetes mellitus	0.000109	0.00219	CcSEcCtD
Linagliptin—Skin disorder—Sitagliptin—type 2 diabetes mellitus	0.000108	0.00218	CcSEcCtD
Linagliptin—Upper respiratory tract infection—Irbesartan—type 2 diabetes mellitus	0.000107	0.00215	CcSEcCtD
Linagliptin—Hypersensitivity—Repaglinide—type 2 diabetes mellitus	0.000107	0.00215	CcSEcCtD
Linagliptin—Pancreatitis—Losartan—type 2 diabetes mellitus	0.000106	0.00214	CcSEcCtD
Linagliptin—Rash—Nateglinide—type 2 diabetes mellitus	0.000106	0.00213	CcSEcCtD
Linagliptin—Dermatitis—Nateglinide—type 2 diabetes mellitus	0.000105	0.00212	CcSEcCtD
Linagliptin—Weight increased—Irbesartan—type 2 diabetes mellitus	0.000105	0.00211	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Pioglitazone—type 2 diabetes mellitus	0.000105	0.00211	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Bromocriptine—type 2 diabetes mellitus	0.000105	0.00211	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Glipizide—type 2 diabetes mellitus	0.000104	0.00209	CcSEcCtD
Linagliptin—Angioedema—Glyburide—type 2 diabetes mellitus	0.000103	0.00208	CcSEcCtD
Linagliptin—Constipation—Glipizide—type 2 diabetes mellitus	0.000103	0.00207	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Sitagliptin—type 2 diabetes mellitus	0.000102	0.00205	CcSEcCtD
Linagliptin—Malnutrition—Gliclazide—type 2 diabetes mellitus	0.000102	0.00205	CcSEcCtD
Linagliptin—DPP4—adipose tissue—type 2 diabetes mellitus	0.000101	0.0838	CbGeAlD
Linagliptin—Upper respiratory tract infection—Losartan—type 2 diabetes mellitus	0.000101	0.00203	CcSEcCtD
Linagliptin—Infection—Bromocriptine—type 2 diabetes mellitus	0.0001	0.00202	CcSEcCtD
Linagliptin—Urinary tract infection—Irbesartan—type 2 diabetes mellitus	9.97e-05	0.00201	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Pioglitazone—type 2 diabetes mellitus	9.92e-05	0.002	CcSEcCtD
Linagliptin—Diarrhoea—Repaglinide—type 2 diabetes mellitus	9.92e-05	0.002	CcSEcCtD
Linagliptin—Weight increased—Losartan—type 2 diabetes mellitus	9.85e-05	0.00199	CcSEcCtD
Linagliptin—Back pain—Gliclazide—type 2 diabetes mellitus	9.82e-05	0.00198	CcSEcCtD
Linagliptin—Skin disorder—Bromocriptine—type 2 diabetes mellitus	9.8e-05	0.00198	CcSEcCtD
Linagliptin—Immune system disorder—Valsartan—type 2 diabetes mellitus	9.68e-05	0.00195	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Glimepiride—type 2 diabetes mellitus	9.66e-05	0.00195	CcSEcCtD
Linagliptin—Mediastinal disorder—Valsartan—type 2 diabetes mellitus	9.66e-05	0.00195	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Sitagliptin—type 2 diabetes mellitus	9.63e-05	0.00194	CcSEcCtD
Linagliptin—Arthralgia—Glyburide—type 2 diabetes mellitus	9.63e-05	0.00194	CcSEcCtD
Linagliptin—Myalgia—Glyburide—type 2 diabetes mellitus	9.63e-05	0.00194	CcSEcCtD
Linagliptin—Immune system disorder—Orlistat—type 2 diabetes mellitus	9.56e-05	0.00193	CcSEcCtD
Linagliptin—Mediastinal disorder—Orlistat—type 2 diabetes mellitus	9.54e-05	0.00192	CcSEcCtD
Linagliptin—Constipation—Sitagliptin—type 2 diabetes mellitus	9.54e-05	0.00192	CcSEcCtD
Linagliptin—Urticaria—Glipizide—type 2 diabetes mellitus	9.53e-05	0.00192	CcSEcCtD
Linagliptin—Urinary tract infection—Losartan—type 2 diabetes mellitus	9.38e-05	0.00189	CcSEcCtD
Linagliptin—Diarrhoea—Rosiglitazone—type 2 diabetes mellitus	9.37e-05	0.00189	CcSEcCtD
Linagliptin—Malnutrition—Valsartan—type 2 diabetes mellitus	9.33e-05	0.00188	CcSEcCtD
Linagliptin—Angioedema—Gliclazide—type 2 diabetes mellitus	9.28e-05	0.00187	CcSEcCtD
Linagliptin—Malnutrition—Orlistat—type 2 diabetes mellitus	9.22e-05	0.00186	CcSEcCtD
Linagliptin—Rash—Repaglinide—type 2 diabetes mellitus	9.14e-05	0.00184	CcSEcCtD
Linagliptin—Dermatitis—Repaglinide—type 2 diabetes mellitus	9.13e-05	0.00184	CcSEcCtD
Linagliptin—Urticaria—Pioglitazone—type 2 diabetes mellitus	9.13e-05	0.00184	CcSEcCtD
Linagliptin—Pancreatitis—Ramipril—type 2 diabetes mellitus	9.1e-05	0.00183	CcSEcCtD
Linagliptin—Headache—Repaglinide—type 2 diabetes mellitus	9.08e-05	0.00183	CcSEcCtD
Linagliptin—Back pain—Valsartan—type 2 diabetes mellitus	9.02e-05	0.00182	CcSEcCtD
Linagliptin—Back pain—Orlistat—type 2 diabetes mellitus	8.92e-05	0.0018	CcSEcCtD
Linagliptin—Urticaria—Glimepiride—type 2 diabetes mellitus	8.89e-05	0.00179	CcSEcCtD
Linagliptin—Urticaria—Sitagliptin—type 2 diabetes mellitus	8.86e-05	0.00179	CcSEcCtD
Linagliptin—Cough—Gliclazide—type 2 diabetes mellitus	8.86e-05	0.00178	CcSEcCtD
Linagliptin—Hypersensitivity—Glipizide—type 2 diabetes mellitus	8.83e-05	0.00178	CcSEcCtD
Linagliptin—Immune system disorder—Metformin—type 2 diabetes mellitus	8.81e-05	0.00178	CcSEcCtD
Linagliptin—Mediastinal disorder—Metformin—type 2 diabetes mellitus	8.79e-05	0.00177	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Bromocriptine—type 2 diabetes mellitus	8.71e-05	0.00176	CcSEcCtD
Linagliptin—Arthralgia—Gliclazide—type 2 diabetes mellitus	8.64e-05	0.00174	CcSEcCtD
Linagliptin—Myalgia—Gliclazide—type 2 diabetes mellitus	8.64e-05	0.00174	CcSEcCtD
Linagliptin—Rash—Rosiglitazone—type 2 diabetes mellitus	8.64e-05	0.00174	CcSEcCtD
Linagliptin—Constipation—Bromocriptine—type 2 diabetes mellitus	8.63e-05	0.00174	CcSEcCtD
Linagliptin—Upper respiratory tract infection—Ramipril—type 2 diabetes mellitus	8.63e-05	0.00174	CcSEcCtD
Linagliptin—Dermatitis—Rosiglitazone—type 2 diabetes mellitus	8.63e-05	0.00174	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Gliclazide—type 2 diabetes mellitus	8.58e-05	0.00173	CcSEcCtD
Linagliptin—Headache—Rosiglitazone—type 2 diabetes mellitus	8.58e-05	0.00173	CcSEcCtD
Linagliptin—Angioedema—Valsartan—type 2 diabetes mellitus	8.52e-05	0.00172	CcSEcCtD
Linagliptin—Malnutrition—Metformin—type 2 diabetes mellitus	8.49e-05	0.00171	CcSEcCtD
Linagliptin—Hypersensitivity—Pioglitazone—type 2 diabetes mellitus	8.46e-05	0.0017	CcSEcCtD
Linagliptin—Weight increased—Ramipril—type 2 diabetes mellitus	8.45e-05	0.0017	CcSEcCtD
Linagliptin—Angioedema—Orlistat—type 2 diabetes mellitus	8.42e-05	0.0017	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Glyburide—type 2 diabetes mellitus	8.41e-05	0.00169	CcSEcCtD
Linagliptin—Immune system disorder—Irbesartan—type 2 diabetes mellitus	8.32e-05	0.00168	CcSEcCtD
Linagliptin—Mediastinal disorder—Irbesartan—type 2 diabetes mellitus	8.3e-05	0.00167	CcSEcCtD
Linagliptin—Hypersensitivity—Glimepiride—type 2 diabetes mellitus	8.24e-05	0.00166	CcSEcCtD
Linagliptin—Infection—Gliclazide—type 2 diabetes mellitus	8.23e-05	0.00166	CcSEcCtD
Linagliptin—Hypersensitivity—Sitagliptin—type 2 diabetes mellitus	8.22e-05	0.00166	CcSEcCtD
Linagliptin—Diarrhoea—Glipizide—type 2 diabetes mellitus	8.2e-05	0.00165	CcSEcCtD
Linagliptin—Cough—Valsartan—type 2 diabetes mellitus	8.14e-05	0.00164	CcSEcCtD
Linagliptin—Skin disorder—Gliclazide—type 2 diabetes mellitus	8.05e-05	0.00162	CcSEcCtD
Linagliptin—Urinary tract infection—Ramipril—type 2 diabetes mellitus	8.05e-05	0.00162	CcSEcCtD
Linagliptin—Cough—Orlistat—type 2 diabetes mellitus	8.04e-05	0.00162	CcSEcCtD
Linagliptin—Urticaria—Bromocriptine—type 2 diabetes mellitus	8.02e-05	0.00162	CcSEcCtD
Linagliptin—Malnutrition—Irbesartan—type 2 diabetes mellitus	8.02e-05	0.00161	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Glyburide—type 2 diabetes mellitus	7.97e-05	0.0016	CcSEcCtD
Linagliptin—Arthralgia—Valsartan—type 2 diabetes mellitus	7.94e-05	0.0016	CcSEcCtD
Linagliptin—Myalgia—Valsartan—type 2 diabetes mellitus	7.94e-05	0.0016	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Valsartan—type 2 diabetes mellitus	7.89e-05	0.00159	CcSEcCtD
Linagliptin—Diarrhoea—Pioglitazone—type 2 diabetes mellitus	7.86e-05	0.00158	CcSEcCtD
Linagliptin—Myalgia—Orlistat—type 2 diabetes mellitus	7.85e-05	0.00158	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Orlistat—type 2 diabetes mellitus	7.79e-05	0.00157	CcSEcCtD
Linagliptin—Diarrhoea—Glimepiride—type 2 diabetes mellitus	7.66e-05	0.00154	CcSEcCtD
Linagliptin—Diarrhoea—Sitagliptin—type 2 diabetes mellitus	7.63e-05	0.00154	CcSEcCtD
Linagliptin—Anaphylactic shock—Valsartan—type 2 diabetes mellitus	7.61e-05	0.00153	CcSEcCtD
Linagliptin—Infection—Valsartan—type 2 diabetes mellitus	7.56e-05	0.00152	CcSEcCtD
Linagliptin—Rash—Glipizide—type 2 diabetes mellitus	7.56e-05	0.00152	CcSEcCtD
Linagliptin—Dermatitis—Glipizide—type 2 diabetes mellitus	7.55e-05	0.00152	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Gliclazide—type 2 diabetes mellitus	7.55e-05	0.00152	CcSEcCtD
Linagliptin—Anaphylactic shock—Orlistat—type 2 diabetes mellitus	7.52e-05	0.00152	CcSEcCtD
Linagliptin—Headache—Glipizide—type 2 diabetes mellitus	7.51e-05	0.00151	CcSEcCtD
Linagliptin—Infection—Orlistat—type 2 diabetes mellitus	7.47e-05	0.00151	CcSEcCtD
Linagliptin—Skin disorder—Valsartan—type 2 diabetes mellitus	7.39e-05	0.00149	CcSEcCtD
Linagliptin—Urticaria—Glyburide—type 2 diabetes mellitus	7.33e-05	0.00148	CcSEcCtD
Linagliptin—Angioedema—Irbesartan—type 2 diabetes mellitus	7.32e-05	0.00148	CcSEcCtD
Linagliptin—Skin disorder—Orlistat—type 2 diabetes mellitus	7.31e-05	0.00147	CcSEcCtD
Linagliptin—Back pain—Losartan—type 2 diabetes mellitus	7.3e-05	0.00147	CcSEcCtD
Linagliptin—Myalgia—Metformin—type 2 diabetes mellitus	7.23e-05	0.00146	CcSEcCtD
Linagliptin—Headache—Pioglitazone—type 2 diabetes mellitus	7.2e-05	0.00145	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Metformin—type 2 diabetes mellitus	7.18e-05	0.00145	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Gliclazide—type 2 diabetes mellitus	7.15e-05	0.00144	CcSEcCtD
Linagliptin—DPP4—liver—type 2 diabetes mellitus	7.11e-05	0.0588	CbGeAlD
Linagliptin—Constipation—Gliclazide—type 2 diabetes mellitus	7.09e-05	0.00143	CcSEcCtD
Linagliptin—Rash—Glimepiride—type 2 diabetes mellitus	7.06e-05	0.00142	CcSEcCtD
Linagliptin—Dermatitis—Glimepiride—type 2 diabetes mellitus	7.05e-05	0.00142	CcSEcCtD
Linagliptin—Rash—Sitagliptin—type 2 diabetes mellitus	7.03e-05	0.00142	CcSEcCtD
Linagliptin—Dermatitis—Sitagliptin—type 2 diabetes mellitus	7.03e-05	0.00142	CcSEcCtD
Linagliptin—Headache—Glimepiride—type 2 diabetes mellitus	7.01e-05	0.00141	CcSEcCtD
Linagliptin—Cough—Irbesartan—type 2 diabetes mellitus	7e-05	0.00141	CcSEcCtD
Linagliptin—Headache—Sitagliptin—type 2 diabetes mellitus	6.99e-05	0.00141	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Valsartan—type 2 diabetes mellitus	6.94e-05	0.0014	CcSEcCtD
Linagliptin—Diarrhoea—Bromocriptine—type 2 diabetes mellitus	6.91e-05	0.00139	CcSEcCtD
Linagliptin—Angioedema—Losartan—type 2 diabetes mellitus	6.89e-05	0.00139	CcSEcCtD
Linagliptin—Infection—Metformin—type 2 diabetes mellitus	6.89e-05	0.00139	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Orlistat—type 2 diabetes mellitus	6.85e-05	0.00138	CcSEcCtD
Linagliptin—Arthralgia—Irbesartan—type 2 diabetes mellitus	6.82e-05	0.00137	CcSEcCtD
Linagliptin—Myalgia—Irbesartan—type 2 diabetes mellitus	6.82e-05	0.00137	CcSEcCtD
Linagliptin—Hypersensitivity—Glyburide—type 2 diabetes mellitus	6.8e-05	0.00137	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Irbesartan—type 2 diabetes mellitus	6.78e-05	0.00137	CcSEcCtD
Linagliptin—Skin disorder—Metformin—type 2 diabetes mellitus	6.73e-05	0.00136	CcSEcCtD
Linagliptin—Immune system disorder—Ramipril—type 2 diabetes mellitus	6.71e-05	0.00135	CcSEcCtD
Linagliptin—Mediastinal disorder—Ramipril—type 2 diabetes mellitus	6.7e-05	0.00135	CcSEcCtD
Linagliptin—Cough—Losartan—type 2 diabetes mellitus	6.58e-05	0.00133	CcSEcCtD
Linagliptin—Urticaria—Gliclazide—type 2 diabetes mellitus	6.58e-05	0.00133	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Valsartan—type 2 diabetes mellitus	6.57e-05	0.00132	CcSEcCtD
Linagliptin—Anaphylactic shock—Irbesartan—type 2 diabetes mellitus	6.54e-05	0.00132	CcSEcCtD
Linagliptin—Constipation—Valsartan—type 2 diabetes mellitus	6.51e-05	0.00131	CcSEcCtD
Linagliptin—Infection—Irbesartan—type 2 diabetes mellitus	6.5e-05	0.00131	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Orlistat—type 2 diabetes mellitus	6.49e-05	0.00131	CcSEcCtD
Linagliptin—Malnutrition—Ramipril—type 2 diabetes mellitus	6.47e-05	0.0013	CcSEcCtD
Linagliptin—Arthralgia—Losartan—type 2 diabetes mellitus	6.42e-05	0.00129	CcSEcCtD
Linagliptin—Myalgia—Losartan—type 2 diabetes mellitus	6.42e-05	0.00129	CcSEcCtD
Linagliptin—Rash—Bromocriptine—type 2 diabetes mellitus	6.36e-05	0.00128	CcSEcCtD
Linagliptin—Dermatitis—Bromocriptine—type 2 diabetes mellitus	6.36e-05	0.00128	CcSEcCtD
Linagliptin—Skin disorder—Irbesartan—type 2 diabetes mellitus	6.35e-05	0.00128	CcSEcCtD
Linagliptin—Headache—Bromocriptine—type 2 diabetes mellitus	6.32e-05	0.00127	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Metformin—type 2 diabetes mellitus	6.32e-05	0.00127	CcSEcCtD
Linagliptin—Diarrhoea—Glyburide—type 2 diabetes mellitus	6.31e-05	0.00127	CcSEcCtD
Linagliptin—Anaphylactic shock—Losartan—type 2 diabetes mellitus	6.16e-05	0.00124	CcSEcCtD
Linagliptin—Infection—Losartan—type 2 diabetes mellitus	6.12e-05	0.00123	CcSEcCtD
Linagliptin—Hypersensitivity—Gliclazide—type 2 diabetes mellitus	6.1e-05	0.00123	CcSEcCtD
Linagliptin—Urticaria—Valsartan—type 2 diabetes mellitus	6.05e-05	0.00122	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Metformin—type 2 diabetes mellitus	5.99e-05	0.00121	CcSEcCtD
Linagliptin—Urticaria—Orlistat—type 2 diabetes mellitus	5.98e-05	0.0012	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Irbesartan—type 2 diabetes mellitus	5.96e-05	0.0012	CcSEcCtD
Linagliptin—Constipation—Metformin—type 2 diabetes mellitus	5.93e-05	0.00119	CcSEcCtD
Linagliptin—Angioedema—Ramipril—type 2 diabetes mellitus	5.91e-05	0.00119	CcSEcCtD
Linagliptin—Rash—Glyburide—type 2 diabetes mellitus	5.82e-05	0.00117	CcSEcCtD
Linagliptin—Dermatitis—Glyburide—type 2 diabetes mellitus	5.81e-05	0.00117	CcSEcCtD
Linagliptin—Headache—Glyburide—type 2 diabetes mellitus	5.78e-05	0.00116	CcSEcCtD
Linagliptin—Diarrhoea—Gliclazide—type 2 diabetes mellitus	5.67e-05	0.00114	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Irbesartan—type 2 diabetes mellitus	5.65e-05	0.00114	CcSEcCtD
Linagliptin—Cough—Ramipril—type 2 diabetes mellitus	5.64e-05	0.00114	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Losartan—type 2 diabetes mellitus	5.61e-05	0.00113	CcSEcCtD
Linagliptin—Hypersensitivity—Valsartan—type 2 diabetes mellitus	5.61e-05	0.00113	CcSEcCtD
Linagliptin—Constipation—Irbesartan—type 2 diabetes mellitus	5.59e-05	0.00113	CcSEcCtD
Linagliptin—Hypersensitivity—Orlistat—type 2 diabetes mellitus	5.54e-05	0.00112	CcSEcCtD
Linagliptin—Urticaria—Metformin—type 2 diabetes mellitus	5.51e-05	0.00111	CcSEcCtD
Linagliptin—Myalgia—Ramipril—type 2 diabetes mellitus	5.51e-05	0.00111	CcSEcCtD
Linagliptin—Arthralgia—Ramipril—type 2 diabetes mellitus	5.51e-05	0.00111	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Ramipril—type 2 diabetes mellitus	5.47e-05	0.0011	CcSEcCtD
Linagliptin—Anaphylactic shock—Ramipril—type 2 diabetes mellitus	5.28e-05	0.00106	CcSEcCtD
Linagliptin—Constipation—Losartan—type 2 diabetes mellitus	5.27e-05	0.00106	CcSEcCtD
Linagliptin—Rash—Gliclazide—type 2 diabetes mellitus	5.22e-05	0.00105	CcSEcCtD
Linagliptin—Dermatitis—Gliclazide—type 2 diabetes mellitus	5.22e-05	0.00105	CcSEcCtD
Linagliptin—Diarrhoea—Valsartan—type 2 diabetes mellitus	5.21e-05	0.00105	CcSEcCtD
Linagliptin—Urticaria—Irbesartan—type 2 diabetes mellitus	5.2e-05	0.00105	CcSEcCtD
Linagliptin—Headache—Gliclazide—type 2 diabetes mellitus	5.19e-05	0.00105	CcSEcCtD
Linagliptin—Diarrhoea—Orlistat—type 2 diabetes mellitus	5.15e-05	0.00104	CcSEcCtD
Linagliptin—Skin disorder—Ramipril—type 2 diabetes mellitus	5.13e-05	0.00103	CcSEcCtD
Linagliptin—Urticaria—Losartan—type 2 diabetes mellitus	4.89e-05	0.000985	CcSEcCtD
Linagliptin—Hypersensitivity—Irbesartan—type 2 diabetes mellitus	4.82e-05	0.000971	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Ramipril—type 2 diabetes mellitus	4.81e-05	0.000969	CcSEcCtD
Linagliptin—Rash—Valsartan—type 2 diabetes mellitus	4.8e-05	0.000967	CcSEcCtD
Linagliptin—Dermatitis—Valsartan—type 2 diabetes mellitus	4.8e-05	0.000966	CcSEcCtD
Linagliptin—Headache—Valsartan—type 2 diabetes mellitus	4.77e-05	0.000961	CcSEcCtD
Linagliptin—Diarrhoea—Metformin—type 2 diabetes mellitus	4.74e-05	0.000956	CcSEcCtD
Linagliptin—Rash—Orlistat—type 2 diabetes mellitus	4.74e-05	0.000956	CcSEcCtD
Linagliptin—Dermatitis—Orlistat—type 2 diabetes mellitus	4.74e-05	0.000955	CcSEcCtD
Linagliptin—Headache—Orlistat—type 2 diabetes mellitus	4.71e-05	0.000949	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Ramipril—type 2 diabetes mellitus	4.56e-05	0.000918	CcSEcCtD
Linagliptin—Hypersensitivity—Losartan—type 2 diabetes mellitus	4.54e-05	0.000914	CcSEcCtD
Linagliptin—Constipation—Ramipril—type 2 diabetes mellitus	4.51e-05	0.00091	CcSEcCtD
Linagliptin—Diarrhoea—Irbesartan—type 2 diabetes mellitus	4.48e-05	0.000902	CcSEcCtD
Linagliptin—Rash—Metformin—type 2 diabetes mellitus	4.37e-05	0.000881	CcSEcCtD
Linagliptin—Dermatitis—Metformin—type 2 diabetes mellitus	4.37e-05	0.00088	CcSEcCtD
Linagliptin—Headache—Metformin—type 2 diabetes mellitus	4.34e-05	0.000875	CcSEcCtD
Linagliptin—Diarrhoea—Losartan—type 2 diabetes mellitus	4.21e-05	0.000849	CcSEcCtD
Linagliptin—Urticaria—Ramipril—type 2 diabetes mellitus	4.19e-05	0.000845	CcSEcCtD
Linagliptin—Rash—Irbesartan—type 2 diabetes mellitus	4.13e-05	0.000831	CcSEcCtD
Linagliptin—Dermatitis—Irbesartan—type 2 diabetes mellitus	4.12e-05	0.00083	CcSEcCtD
Linagliptin—Headache—Irbesartan—type 2 diabetes mellitus	4.1e-05	0.000826	CcSEcCtD
Linagliptin—Hypersensitivity—Ramipril—type 2 diabetes mellitus	3.89e-05	0.000784	CcSEcCtD
Linagliptin—Rash—Losartan—type 2 diabetes mellitus	3.88e-05	0.000782	CcSEcCtD
Linagliptin—Dermatitis—Losartan—type 2 diabetes mellitus	3.88e-05	0.000781	CcSEcCtD
Linagliptin—Headache—Losartan—type 2 diabetes mellitus	3.86e-05	0.000777	CcSEcCtD
Linagliptin—ABCB1—islet of Langerhans—type 2 diabetes mellitus	3.67e-05	0.0303	CbGeAlD
Linagliptin—CYP3A4—kidney—type 2 diabetes mellitus	3.67e-05	0.0303	CbGeAlD
Linagliptin—Diarrhoea—Ramipril—type 2 diabetes mellitus	3.61e-05	0.000728	CcSEcCtD
Linagliptin—Rash—Ramipril—type 2 diabetes mellitus	3.33e-05	0.000671	CcSEcCtD
Linagliptin—Dermatitis—Ramipril—type 2 diabetes mellitus	3.33e-05	0.00067	CcSEcCtD
Linagliptin—Headache—Ramipril—type 2 diabetes mellitus	3.31e-05	0.000666	CcSEcCtD
Linagliptin—ABCB1—retina—type 2 diabetes mellitus	3.14e-05	0.0259	CbGeAlD
Linagliptin—ABCB1—nephron tubule—type 2 diabetes mellitus	2.95e-05	0.0244	CbGeAlD
Linagliptin—ABCB1—cardiovascular system—type 2 diabetes mellitus	2.65e-05	0.0219	CbGeAlD
Linagliptin—ABCB1—kidney—type 2 diabetes mellitus	2.6e-05	0.0215	CbGeAlD
Linagliptin—ABCB1—pancreas—type 2 diabetes mellitus	2.58e-05	0.0213	CbGeAlD
Linagliptin—ABCB1—cortex of kidney—type 2 diabetes mellitus	2.53e-05	0.0209	CbGeAlD
Linagliptin—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2E1—type 2 diabetes mellitus	2.39e-05	0.00107	CbGpPWpGaD
Linagliptin—CYP3A4—Tryptophan metabolism—CAT—type 2 diabetes mellitus	2.37e-05	0.00106	CbGpPWpGaD
Linagliptin—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A2—type 2 diabetes mellitus	2.37e-05	0.00105	CbGpPWpGaD
Linagliptin—CYP3A4—Oxidation by Cytochrome P450—CYP2E1—type 2 diabetes mellitus	2.36e-05	0.00105	CbGpPWpGaD
Linagliptin—CYP3A4—Phase 1 - Functionalization of compounds—CYP11A1—type 2 diabetes mellitus	2.35e-05	0.00105	CbGpPWpGaD
Linagliptin—ABCB1—adipose tissue—type 2 diabetes mellitus	2.34e-05	0.0194	CbGeAlD
Linagliptin—CYP3A4—Oxidation by Cytochrome P450—CYP1A2—type 2 diabetes mellitus	2.33e-05	0.00104	CbGpPWpGaD
Linagliptin—CYP3A4—liver—type 2 diabetes mellitus	2.32e-05	0.0192	CbGeAlD
Linagliptin—ABCB1—HIF-1-alpha transcription factor network—HIF1A—type 2 diabetes mellitus	2.3e-05	0.00102	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—SLC26A9—type 2 diabetes mellitus	2.26e-05	0.001	CbGpPWpGaD
Linagliptin—ABCB1—HIF-1-alpha transcription factor network—LEP—type 2 diabetes mellitus	2.24e-05	0.000999	CbGpPWpGaD
Linagliptin—DPP4—Metabolism of proteins—MMP1—type 2 diabetes mellitus	2.15e-05	0.000956	CbGpPWpGaD
Linagliptin—DPP4—Metabolism of proteins—AGT—type 2 diabetes mellitus	2.12e-05	0.000944	CbGpPWpGaD
Linagliptin—ABCB1—Allograft Rejection—FAS—type 2 diabetes mellitus	2.12e-05	0.000942	CbGpPWpGaD
Linagliptin—ABCB1—HIF-1-alpha transcription factor network—NOS2—type 2 diabetes mellitus	2.09e-05	0.000931	CbGpPWpGaD
Linagliptin—ABCB1—Allograft Rejection—C3—type 2 diabetes mellitus	2.09e-05	0.000929	CbGpPWpGaD
Linagliptin—DPP4—Metabolism of proteins—LEP—type 2 diabetes mellitus	2.08e-05	0.000925	CbGpPWpGaD
Linagliptin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—type 2 diabetes mellitus	2.05e-05	0.000911	CbGpPWpGaD
Linagliptin—CYP3A4—Phase 1 - Functionalization of compounds—CYP2E1—type 2 diabetes mellitus	1.94e-05	0.000863	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—HNF4A—type 2 diabetes mellitus	1.92e-05	0.000856	CbGpPWpGaD
Linagliptin—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A2—type 2 diabetes mellitus	1.92e-05	0.000854	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—IAPP—type 2 diabetes mellitus	1.86e-05	0.000829	CbGpPWpGaD
Linagliptin—DPP4—Metabolism of proteins—INS—type 2 diabetes mellitus	1.77e-05	0.00079	CbGpPWpGaD
Linagliptin—ABCB1—HIF-1-alpha transcription factor network—SERPINE1—type 2 diabetes mellitus	1.76e-05	0.000784	CbGpPWpGaD
Linagliptin—DPP4—Metabolism of proteins—CCL2—type 2 diabetes mellitus	1.75e-05	0.000777	CbGpPWpGaD
Linagliptin—DPP4—Metabolism of proteins—IGF1—type 2 diabetes mellitus	1.72e-05	0.000764	CbGpPWpGaD
Linagliptin—ABCB1—liver—type 2 diabetes mellitus	1.64e-05	0.0136	CbGeAlD
Linagliptin—ABCB1—Allograft Rejection—CASP8—type 2 diabetes mellitus	1.63e-05	0.000727	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—TNFRSF1A—type 2 diabetes mellitus	1.52e-05	0.000677	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—SLC5A4—type 2 diabetes mellitus	1.51e-05	0.00067	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—TRPC1—type 2 diabetes mellitus	1.45e-05	0.000647	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—G6PC—type 2 diabetes mellitus	1.45e-05	0.000647	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—AR—type 2 diabetes mellitus	1.33e-05	0.000594	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—PLN—type 2 diabetes mellitus	1.33e-05	0.000592	CbGpPWpGaD
Linagliptin—CYP3A4—Biological oxidations—MTR—type 2 diabetes mellitus	1.29e-05	0.000574	CbGpPWpGaD
Linagliptin—CYP3A4—Biological oxidations—CYP11A1—type 2 diabetes mellitus	1.25e-05	0.000556	CbGpPWpGaD
Linagliptin—ABCB1—Allograft Rejection—CASP3—type 2 diabetes mellitus	1.24e-05	0.00055	CbGpPWpGaD
Linagliptin—CYP3A4—Metapathway biotransformation—CYP11A1—type 2 diabetes mellitus	1.23e-05	0.000548	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN2B—type 2 diabetes mellitus	1.23e-05	0.000547	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—SIRT1—type 2 diabetes mellitus	1.22e-05	0.000541	CbGpPWpGaD
Linagliptin—ABCB1—HIF-1-alpha transcription factor network—VEGFA—type 2 diabetes mellitus	1.21e-05	0.000539	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—SLC30A8—type 2 diabetes mellitus	1.19e-05	0.000528	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—ABCC8—type 2 diabetes mellitus	1.19e-05	0.000528	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—COX2—type 2 diabetes mellitus	1.14e-05	0.000508	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—SLC5A2—type 2 diabetes mellitus	1.14e-05	0.000508	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—NCOA6—type 2 diabetes mellitus	1.12e-05	0.000499	CbGpPWpGaD
Linagliptin—ABCB1—Allograft Rejection—VEGFA—type 2 diabetes mellitus	1.05e-05	0.000467	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—type 2 diabetes mellitus	1.04e-05	0.000465	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—ATP2A3—type 2 diabetes mellitus	1.04e-05	0.000461	CbGpPWpGaD
Linagliptin—CYP3A4—Biological oxidations—CYP2E1—type 2 diabetes mellitus	1.03e-05	0.000459	CbGpPWpGaD
Linagliptin—CYP3A4—Biological oxidations—CYP1A2—type 2 diabetes mellitus	1.02e-05	0.000453	CbGpPWpGaD
Linagliptin—CYP3A4—Metapathway biotransformation—CYP2E1—type 2 diabetes mellitus	1.02e-05	0.000452	CbGpPWpGaD
Linagliptin—CYP3A4—Metapathway biotransformation—CYP1A2—type 2 diabetes mellitus	1e-05	0.000447	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—HK1—type 2 diabetes mellitus	9.7e-06	0.000432	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—BHMT—type 2 diabetes mellitus	9.66e-06	0.00043	CbGpPWpGaD
Linagliptin—ABCB1—Allograft Rejection—TGFB1—type 2 diabetes mellitus	9.62e-06	0.000428	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—GCKR—type 2 diabetes mellitus	9.37e-06	0.000417	CbGpPWpGaD
Linagliptin—ABCB1—Allograft Rejection—TNF—type 2 diabetes mellitus	8.99e-06	0.0004	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—ABCC2—type 2 diabetes mellitus	8.98e-06	0.0004	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—PTGDS—type 2 diabetes mellitus	8.45e-06	0.000376	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—AANAT—type 2 diabetes mellitus	8.45e-06	0.000376	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—CASP8—type 2 diabetes mellitus	8.06e-06	0.000359	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—GPD2—type 2 diabetes mellitus	8.01e-06	0.000357	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—CDO1—type 2 diabetes mellitus	8.01e-06	0.000357	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—type 2 diabetes mellitus	7.92e-06	0.000353	CbGpPWpGaD
Linagliptin—CYP3A4—Biological oxidations—GSTM1—type 2 diabetes mellitus	7.81e-06	0.000348	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—SLC2A2—type 2 diabetes mellitus	7.8e-06	0.000347	CbGpPWpGaD
Linagliptin—ABCB1—HIF-1-alpha transcription factor network—AKT1—type 2 diabetes mellitus	7.73e-06	0.000344	CbGpPWpGaD
Linagliptin—CYP3A4—Metapathway biotransformation—GSTM1—type 2 diabetes mellitus	7.7e-06	0.000343	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—AK1—type 2 diabetes mellitus	7.64e-06	0.00034	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—ATP2A2—type 2 diabetes mellitus	7.44e-06	0.000331	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—GCK—type 2 diabetes mellitus	7.44e-06	0.000331	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—SLC9A1—type 2 diabetes mellitus	7.26e-06	0.000323	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—TRPC6—type 2 diabetes mellitus	7.22e-06	0.000321	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—CETP—type 2 diabetes mellitus	7.18e-06	0.00032	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—MAT1A—type 2 diabetes mellitus	7.05e-06	0.000314	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—SLC5A4—type 2 diabetes mellitus	7.05e-06	0.000314	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—BCL2—type 2 diabetes mellitus	6.92e-06	0.000308	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—PPP1R3C—type 2 diabetes mellitus	6.81e-06	0.000303	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—ENPP1—type 2 diabetes mellitus	6.81e-06	0.000303	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—ND1—type 2 diabetes mellitus	6.81e-06	0.000303	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—HBA2—type 2 diabetes mellitus	6.81e-06	0.000303	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—G6PC—type 2 diabetes mellitus	6.81e-06	0.000303	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—GCGR—type 2 diabetes mellitus	6.59e-06	0.000294	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—type 2 diabetes mellitus	6.57e-06	0.000292	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—PLAT—type 2 diabetes mellitus	6.33e-06	0.000282	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—CYTB—type 2 diabetes mellitus	6.23e-06	0.000277	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—OXCT1—type 2 diabetes mellitus	6.23e-06	0.000277	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—type 2 diabetes mellitus	6.1e-06	0.000271	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—SRD5A1—type 2 diabetes mellitus	6.07e-06	0.00027	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—SLC2A1—type 2 diabetes mellitus	6.04e-06	0.000269	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—BHMT—type 2 diabetes mellitus	5.95e-06	0.000265	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—HSD17B3—type 2 diabetes mellitus	5.79e-06	0.000258	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—STAR—type 2 diabetes mellitus	5.79e-06	0.000258	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—ACACA—type 2 diabetes mellitus	5.79e-06	0.000258	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—SLC2A4—type 2 diabetes mellitus	5.79e-06	0.000258	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—type 2 diabetes mellitus	5.7e-06	0.000254	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—ABCC8—type 2 diabetes mellitus	5.55e-06	0.000247	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—CBS—type 2 diabetes mellitus	5.55e-06	0.000247	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—COX2—type 2 diabetes mellitus	5.34e-06	0.000238	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—SLC5A2—type 2 diabetes mellitus	5.34e-06	0.000238	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—type 2 diabetes mellitus	5.31e-06	0.000237	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—NCOA6—type 2 diabetes mellitus	5.25e-06	0.000234	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—PTGDS—type 2 diabetes mellitus	5.2e-06	0.000232	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—AANAT—type 2 diabetes mellitus	5.2e-06	0.000232	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—type 2 diabetes mellitus	5.17e-06	0.00023	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—UCP2—type 2 diabetes mellitus	5.16e-06	0.00023	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—HSD11B1—type 2 diabetes mellitus	5.16e-06	0.00023	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—UCP3—type 2 diabetes mellitus	5.16e-06	0.00023	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—GNB3—type 2 diabetes mellitus	4.99e-06	0.000222	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—HMOX1—type 2 diabetes mellitus	4.97e-06	0.000221	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—GPD2—type 2 diabetes mellitus	4.93e-06	0.00022	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—CDO1—type 2 diabetes mellitus	4.93e-06	0.00022	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—AVP—type 2 diabetes mellitus	4.92e-06	0.000219	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—PCK1—type 2 diabetes mellitus	4.85e-06	0.000216	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—APOB—type 2 diabetes mellitus	4.76e-06	0.000212	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—type 2 diabetes mellitus	4.75e-06	0.000211	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—AK1—type 2 diabetes mellitus	4.71e-06	0.00021	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—type 2 diabetes mellitus	4.66e-06	0.000207	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—HK1—type 2 diabetes mellitus	4.54e-06	0.000202	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—ADCY5—type 2 diabetes mellitus	4.45e-06	0.000198	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—type 2 diabetes mellitus	4.44e-06	0.000197	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—GCKR—type 2 diabetes mellitus	4.39e-06	0.000195	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—HSD3B2—type 2 diabetes mellitus	4.39e-06	0.000195	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—KCNJ11—type 2 diabetes mellitus	4.39e-06	0.000195	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—LPA—type 2 diabetes mellitus	4.39e-06	0.000195	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—SLC5A4—type 2 diabetes mellitus	4.34e-06	0.000193	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—MAT1A—type 2 diabetes mellitus	4.34e-06	0.000193	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—ALDOB—type 2 diabetes mellitus	4.21e-06	0.000187	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—ND1—type 2 diabetes mellitus	4.2e-06	0.000187	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—ENPP1—type 2 diabetes mellitus	4.2e-06	0.000187	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—PPP1R3C—type 2 diabetes mellitus	4.2e-06	0.000187	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—HBA2—type 2 diabetes mellitus	4.2e-06	0.000187	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—G6PC—type 2 diabetes mellitus	4.2e-06	0.000187	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—GCGR—type 2 diabetes mellitus	4.06e-06	0.000181	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—PPARA—type 2 diabetes mellitus	4.01e-06	0.000179	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—GLP1R—type 2 diabetes mellitus	3.91e-06	0.000174	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—OXCT1—type 2 diabetes mellitus	3.84e-06	0.000171	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—CYTB—type 2 diabetes mellitus	3.84e-06	0.000171	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—APOA1—type 2 diabetes mellitus	3.76e-06	0.000168	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—SRD5A1—type 2 diabetes mellitus	3.74e-06	0.000166	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—SLC2A2—type 2 diabetes mellitus	3.65e-06	0.000163	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—MTR—type 2 diabetes mellitus	3.58e-06	0.000159	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—CPT1A—type 2 diabetes mellitus	3.58e-06	0.000159	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—STAR—type 2 diabetes mellitus	3.57e-06	0.000159	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—ACACA—type 2 diabetes mellitus	3.57e-06	0.000159	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—HSD17B3—type 2 diabetes mellitus	3.57e-06	0.000159	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—NAMPT—type 2 diabetes mellitus	3.51e-06	0.000156	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—LIPC—type 2 diabetes mellitus	3.49e-06	0.000155	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—HBA1—type 2 diabetes mellitus	3.49e-06	0.000155	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—GCK—type 2 diabetes mellitus	3.49e-06	0.000155	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—CYP11A1—type 2 diabetes mellitus	3.46e-06	0.000154	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—ABCC8—type 2 diabetes mellitus	3.42e-06	0.000152	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—CBS—type 2 diabetes mellitus	3.42e-06	0.000152	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—SLC9A1—type 2 diabetes mellitus	3.4e-06	0.000151	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—CETP—type 2 diabetes mellitus	3.36e-06	0.00015	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—type 2 diabetes mellitus	3.3e-06	0.000147	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—COX2—type 2 diabetes mellitus	3.29e-06	0.000147	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—SLC5A2—type 2 diabetes mellitus	3.29e-06	0.000147	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—NCOA6—type 2 diabetes mellitus	3.23e-06	0.000144	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—HSD11B1—type 2 diabetes mellitus	3.18e-06	0.000142	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—UCP2—type 2 diabetes mellitus	3.18e-06	0.000142	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—UCP3—type 2 diabetes mellitus	3.18e-06	0.000142	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—PSMD6—type 2 diabetes mellitus	3.13e-06	0.000139	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—SREBF1—type 2 diabetes mellitus	3.13e-06	0.000139	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—SNAP25—type 2 diabetes mellitus	3.13e-06	0.000139	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—CTGF—type 2 diabetes mellitus	3.07e-06	0.000137	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—HMGCR—type 2 diabetes mellitus	3.04e-06	0.000135	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—PCK1—type 2 diabetes mellitus	2.99e-06	0.000133	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—ALB—type 2 diabetes mellitus	2.98e-06	0.000133	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—ADRA2A—type 2 diabetes mellitus	2.98e-06	0.000132	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—CYP2E1—type 2 diabetes mellitus	2.86e-06	0.000127	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—SLC2A1—type 2 diabetes mellitus	2.83e-06	0.000126	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—CYP1A2—type 2 diabetes mellitus	2.83e-06	0.000126	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—HK1—type 2 diabetes mellitus	2.8e-06	0.000125	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—CYP3A4—type 2 diabetes mellitus	2.76e-06	0.000123	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—GCG—type 2 diabetes mellitus	2.71e-06	0.000121	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—SLC2A4—type 2 diabetes mellitus	2.71e-06	0.000121	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—HSD3B2—type 2 diabetes mellitus	2.7e-06	0.00012	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—KCNJ11—type 2 diabetes mellitus	2.7e-06	0.00012	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—GCKR—type 2 diabetes mellitus	2.7e-06	0.00012	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—LPA—type 2 diabetes mellitus	2.7e-06	0.00012	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—ALDOB—type 2 diabetes mellitus	2.59e-06	0.000115	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—GLP1R—type 2 diabetes mellitus	2.41e-06	0.000107	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—GNB3—type 2 diabetes mellitus	2.34e-06	0.000104	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—PPARGC1A—type 2 diabetes mellitus	2.34e-06	0.000104	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—HMOX1—type 2 diabetes mellitus	2.33e-06	0.000104	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—CAT—type 2 diabetes mellitus	2.29e-06	0.000102	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—SLC2A2—type 2 diabetes mellitus	2.25e-06	0.0001	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—APOB—type 2 diabetes mellitus	2.23e-06	9.92e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—CPT1A—type 2 diabetes mellitus	2.2e-06	9.81e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—MTR—type 2 diabetes mellitus	2.2e-06	9.81e-05	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—GSTM1—type 2 diabetes mellitus	2.17e-06	9.65e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—NAMPT—type 2 diabetes mellitus	2.16e-06	9.62e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—HBA1—type 2 diabetes mellitus	2.15e-06	9.56e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—LIPC—type 2 diabetes mellitus	2.15e-06	9.56e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—GCK—type 2 diabetes mellitus	2.15e-06	9.56e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—CYP11A1—type 2 diabetes mellitus	2.13e-06	9.5e-05	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—LPL—type 2 diabetes mellitus	2.13e-06	9.47e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—SLC9A1—type 2 diabetes mellitus	2.1e-06	9.33e-05	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—ADCY5—type 2 diabetes mellitus	2.08e-06	9.27e-05	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—GPX1—type 2 diabetes mellitus	2.08e-06	9.24e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—CETP—type 2 diabetes mellitus	2.07e-06	9.22e-05	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—CD36—type 2 diabetes mellitus	2.02e-06	9e-05	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—PPP2CA—type 2 diabetes mellitus	2e-06	8.88e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—PSMD6—type 2 diabetes mellitus	1.93e-06	8.58e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—SREBF1—type 2 diabetes mellitus	1.93e-06	8.58e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—SNAP25—type 2 diabetes mellitus	1.93e-06	8.58e-05	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—MTHFR—type 2 diabetes mellitus	1.92e-06	8.53e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—CTGF—type 2 diabetes mellitus	1.89e-06	8.42e-05	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—PPARA—type 2 diabetes mellitus	1.88e-06	8.36e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—HMGCR—type 2 diabetes mellitus	1.87e-06	8.34e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—ADRA2A—type 2 diabetes mellitus	1.83e-06	8.16e-05	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—AGT—type 2 diabetes mellitus	1.82e-06	8.1e-05	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—CALM1—type 2 diabetes mellitus	1.79e-06	7.97e-05	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—APOE—type 2 diabetes mellitus	1.78e-06	7.94e-05	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—APOA1—type 2 diabetes mellitus	1.76e-06	7.85e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—CYP2E1—type 2 diabetes mellitus	1.76e-06	7.84e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—CYP1A2—type 2 diabetes mellitus	1.74e-06	7.76e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—SLC2A1—type 2 diabetes mellitus	1.74e-06	7.76e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—GCG—type 2 diabetes mellitus	1.67e-06	7.44e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—SLC2A4—type 2 diabetes mellitus	1.67e-06	7.44e-05	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—PPARG—type 2 diabetes mellitus	1.55e-06	6.91e-05	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—INS—type 2 diabetes mellitus	1.52e-06	6.78e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—PPARGC1A—type 2 diabetes mellitus	1.44e-06	6.41e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—GNB3—type 2 diabetes mellitus	1.44e-06	6.41e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—HMOX1—type 2 diabetes mellitus	1.43e-06	6.38e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—CAT—type 2 diabetes mellitus	1.41e-06	6.29e-05	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—ALB—type 2 diabetes mellitus	1.4e-06	6.22e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—APOB—type 2 diabetes mellitus	1.37e-06	6.11e-05	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—PIK3R1—type 2 diabetes mellitus	1.34e-06	5.95e-05	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—NOS3—type 2 diabetes mellitus	1.34e-06	5.95e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—GSTM1—type 2 diabetes mellitus	1.34e-06	5.94e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—LPL—type 2 diabetes mellitus	1.31e-06	5.83e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—ADCY5—type 2 diabetes mellitus	1.28e-06	5.71e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—GPX1—type 2 diabetes mellitus	1.28e-06	5.69e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—CD36—type 2 diabetes mellitus	1.25e-06	5.54e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—PPP2CA—type 2 diabetes mellitus	1.23e-06	5.47e-05	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—PTGS2—type 2 diabetes mellitus	1.22e-06	5.44e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—MTHFR—type 2 diabetes mellitus	1.18e-06	5.25e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—PPARA—type 2 diabetes mellitus	1.16e-06	5.15e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—AGT—type 2 diabetes mellitus	1.12e-06	4.99e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—CALM1—type 2 diabetes mellitus	1.1e-06	4.91e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—APOE—type 2 diabetes mellitus	1.1e-06	4.89e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—APOA1—type 2 diabetes mellitus	1.09e-06	4.83e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—PPARG—type 2 diabetes mellitus	9.57e-07	4.26e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—INS—type 2 diabetes mellitus	9.38e-07	4.18e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—ALB—type 2 diabetes mellitus	8.6e-07	3.83e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—NOS3—type 2 diabetes mellitus	8.23e-07	3.66e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—PIK3R1—type 2 diabetes mellitus	8.23e-07	3.66e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—PTGS2—type 2 diabetes mellitus	7.53e-07	3.35e-05	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—AKT1—type 2 diabetes mellitus	6.14e-07	2.73e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—AKT1—type 2 diabetes mellitus	3.78e-07	1.68e-05	CbGpPWpGaD
